Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass: A Blinded Randomized Control Trial Comparing Two Strategies

NCT05426031 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT05426031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass: A Blinded Randomized Control Trial Comparing Two Strategies
Lead sponsor
University of Miami
Phase
Phase 4
Overall status
Completed
Start date
June 28, 2022
Completion date
June 1, 2023
Enrollment
130 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coagulation; intravascular